Cannabis Rescheduling Is Here.

Why it Matters Now

Immediate Impacts

  • Immediate earnings impact – removal of 280E tax penalties could significantly boost net income and free cash flow for top multi-state operators (MSOs).
  • Improved capital access – lower financing costs and expanded lending channels create a healthier capital structure for leading operators.
  • Institutional participation – the shift paves the way for broader investor access, which can improve liquidity and support valuations.
  • Attractive entry point – valuations remain well below historical peaks, offering potential upside as fundamentals and market access improve.

Potential Future Impacts

Potential Impacts

  • Uplisting to Major Exchanges – Regulatory clarity could allow U.S. plant-touching operators to list on the NYSE or Nasdaq, expanding their investor base and improving liquidity.
  • Banking Integration – Access to mainstream banking and payment solutions could reduce cash-handling risks, lower compliance costs, and streamline operations.
  • Index Inclusion – Eligibility for major U.S. and global equity indices would open the door for passive and index-linked investment flows from ETFs, pensions, and mutual funds.
  • Lower Cost of Capital – As credit spreads tighten and new lending sources emerge, operators could finance growth initiatives at materially lower rates.

Different Ways to Access the Cannabis Theme:

Accessing the cannabis theme can be an important way to position for one of the most significant policy changes the industry has experienced. Investors have several approaches to consider, each with different exposures and risk levels.

A U.S.-focused strategy targeting domestic multi-state operators and companies positioned to benefit directly from regulatory changes in the United States.

A global strategy expanding the opportunity set to include companies in established and emerging cannabis markets around the world.

A leveraged strategy offering amplified, short-term exposure to the theme — intended only for experienced investors who understand the potential for both greater gains and losses.

Questions? We’re Here for You.

Your clients count on you to spot the right opportunities. We’re here to support you with resources, including direct access to our portfolio managers, so you can stay ahead and confidently guide your clients.

What 280E was (Schedule I/II):
Section 280E barred cannabis operators from deducting ordinary business expenses like payroll, rent, interest, and SG&A. Only cost of goods sold was deductible. That pushed effective tax rates dramatically higher than typical corporations.

Quick example:
A dispensary with $100 of pre-tax income that previously faced a 60–80% effective tax rate kept only $20–40. Post-rescheduling, assuming ~25–30% combined tax, it could keep ~$70–75. The spread can fund store buildouts, hiring, and debt reduction.

What Schedule III means now:
With cannabis moved to Schedule III, 280E no longer applies. Licensed operators can deduct normal business expenses like any other company, aligning toward standard corporate tax rates (federal 21% plus applicable state). Expect higher after-tax margins and stronger free cash flow as 280E is removed. 

A century ago, alcohol Prohibition created a thriving illicit market, swelled enforcement costs, and was ultimately repealed as policy as public opinion towards alcohol shifted. Today’s cannabis transition could echo that arc: evolving norms, pragmatic regulation, new tax revenues, and potential displacement of illegal production.

But emerging themes are volatile and involve risk

Like post-Prohibition alcohol, legalization is a process, not a switch. A diversified, actively managed approach can help navigate regulatory phases, price cycles, and company dispersion while keeping exposure to the secular opportunity. MSOS provides targeted, actively managed access to U.S. operators at the center of this transition—while YOLO (broader, global exposure) and MSOX (leveraged exposure to MSOS) offer alternative ways to express the theme based on mandate and risk tolerance.

Drugs, substances, and certain chemicals used to make drugs are classified into five distinct categories or schedules depending upon the drug’s acceptable medical use and the drug’s abuse or dependency potential. The abuse rate is a determinate factor in the scheduling of the drug; for example, Schedule I drugs have a high potential for abuse and the potential to create severe psychological and/or physical dependence. As the drug schedule changes — Schedule II, Schedule III, etc., so does the abuse potential — Schedule V drugs represents the least potential for abuse.

The U.S. Drug Enforcement Agency (DEA) or the U.S. Congress can place a substance in a schedule, move a controlled substance to a different schedule, or remove a controlled substance from a schedule.

Schedule I

Schedule I drugs, substances, or chemicals are defined as drugs with no currently accepted medical use and a high potential for abuse. Some examples of Schedule I drugs are: heroin, lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (ecstasy), methaqualone, and peyote. Cannabis (marijuana) was formerly classified as a Schedule I drug.

Schedule II

Schedule II drugs, substances, or chemicals are defined as drugs with a high potential for abuse, with use potentially leading to severe psychological or physical dependence. These drugs are also considered dangerous. Some examples of Schedule II drugs are: combination products with less than 15 milligrams of hydrocodone per dosage unit (Vicodin), cocaine, methamphetamine, methadone, hydromorphone (Dilaudid), meperidine (Demerol), oxycodone (OxyContin), fentanyl, Dexedrine, Adderall, and Ritalin.

Schedule III

Schedule III drugs, substances, or chemicals are defined as drugs with a moderate to low potential for physical and psychological dependence. Schedule III drugs abuse potential is less than Schedule I and Schedule II drugs but more than Schedule IV. Some examples of Schedule III drugs are: products containing less than 90 milligrams of codeine per dosage unit (Tylenol with codeine), ketamine, anabolic steroids, testosterone. Cannabis (marijuana) has been rescheduled as a Schedule III drug.

Schedule IV

Schedule IV drugs, substances, or chemicals are defined as drugs with a low potential for abuse and low risk of dependence. Some examples of Schedule IV drugs are: Xanax, Soma, Darvon, Darvocet, Valium, Ativan, Talwin, Ambien, Tramadol.

Schedule V

Schedule V drugs, substances, or chemicals are defined as drugs with lower potential for abuse than Schedule IV and consist of preparations containing limited quantities of certain narcotics. Schedule V drugs are generally used for antidiarrheal, antitussive, and analgesic purposes. Some examples of Schedule V drugs are: cough preparations with less than 200 milligrams of codeine or per 100 milliliters (Robitussin AC), Lomotil, Motofen, Lyrica, Parepectolin.

Source: www.dea.gov

Different Ways to Access the Cannabis Theme:

Before investing you should carefully consider the Fund’s investment objectives, risks, charges and expenses. This and other information is in the prospectus, a copy of which may be obtained by visiting the Fund’s website at www.AdvisorShares.com. Please read the prospectus carefully before you invest. Foreside Fund Services, LLC, distributor.
 
The Fund(s) is subject to a number of risks that may affect the value of its shares. This section provides additional information about the Fund’s principal risks. The degree to which a risk applies to the Fund(s) varies according to its investment allocation. Each investor should review the complete description of the principal risks before investing in the Fund(s). As with investing in other securities whose prices increase and decrease in market value, you may lose money by investing in the Fund(s).
 
Cannabis-Related Company Risk: Cannabis-related companies are subject to various laws and regulations that may differ at the state/local and federal level. These laws and regulations may (i) significantly affect a cannabis-related company’s ability to secure financing, (ii) impact the market for marijuana industry sales and services, and (iii) set limitations on marijuana use, production, transportation, and storage. Cannabis-related companies may also be required to secure permits and authorizations from government agencies to cultivate or research marijuana. In addition, cannabis-related companies are subject to the risks associated with the greater agricultural industry, including changes to or trends that affect commodity prices, labor costs, weather conditions, and laws and regulations related to environmental protection, health and safety. Cannabis-related companies may also be subject to risks associated with the biotechnology and pharmaceutical industries. These risks include increased government regulation, the use and enforcement of intellectual property rights and patents, technological change and obsolescence, product liability lawsuits, and the risk that research and development may not necessarily lead to commercially successful products.
 
Leverage Risk: Leverage is investment exposure that exceeds the initial amount invested. The loss on a leveraged investment may far exceed the Fund’s principal amount invested. Leverage may magnify the Fund’s gains and losses and, therefore, increase volatility. The use of leverage may result in the Fund having to liquidate holdings when it may not be advantageous to do so. IPO Risk: The Fund may invest in securities offered in IPOs or in companies that have recently completed an IPO. The market value of IPO shares can have significant volatility due to factors such as the absence of a prior public market, unseasoned trading, a small number of shares available for trading and limited information about the issuer. MSOX The Fund is an actively managed ETF that seeks to provide investment results that are two times (2x) the daily total return, before fees and expenses, of the AdvisorShares Pure US Cannabis ETF, an affiliated ETF, by entering into one or more swaps agreements on the US Cannabis ETF. The Fund does not seek to achieve its stated investment objective for a period of time different than a single day.
 
A single day is measured from the time the Fund calculates its net asset value (“NAV”) to the time of the Fund’s next NAV calculation. The Fund will enter into one or more swap agreements intended to produce economically-leveraged investment results relative to the returns of the US Cannabis ETF. The Fund may use a combination of swaps on the US Cannabis ETF and swaps on various investment vehicles that are designed to track the performance of the US Cannabis ETF. The Fund expects that cash balances in connection with the use of such financial instruments (“Collateral”) will typically be held in money market.
AIL-796906-2025-08-29